Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Unión Europea. Comisión Europea. H2020
    • بيانات النشر:
      European Centre for Disease Prevention and Control (ECDC)
    • الموضوع:
      2021
    • Collection:
      REPISALUD (REPositorio Institucional en SALUD del Instituto de Salud Carlos III - ISCIII)
    • نبذة مختصرة :
      We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals. ; This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. ; Sí
    • ISSN:
      1560-7917
    • Relation:
      https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670; info:eu-repo/grantAgreement/EC/H2020/101003673/EU; Euro Surveill. 2021;26(29):2100670.; http://hdl.handle.net/20.500.12105/14166; Euro Surveillance: bulletin Europeen sur les maladies transmissibles
    • الرقم المعرف:
      10.2807/1560-7917.ES.2021.26.29.2100670
    • Rights:
      http://creativecommons.org/licenses/by/4.0/ ; Atribución 4.0 Internacional ; open access
    • الرقم المعرف:
      edsbas.34BE303A